Q2 2017 13F Holders as of 30 Jun 2017
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
107,800,271
-
Number of holders
-
99
-
Total 13F shares, excl. options
-
30,949,779
-
Shares change
-
+1,642,302
-
Total reported value, excl. options
-
$384,461,374
-
Value change
-
+$12,666,882
-
Put/Call ratio
-
13%
-
Number of buys
-
44
-
Number of sells
-
-53
-
Price
-
$12.42
Significant Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q2 2017
136 filings reported holding ITCI - Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share as of Q2 2017.
Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) has 99 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 30,949,779 shares
of 107,800,271 outstanding shares and own 29% of the company stock.
Largest 10 shareholders include FMR LLC (6,513,071 shares), BlackRock Inc. (3,835,751 shares), VANGUARD GROUP INC (2,721,732 shares), BB BIOTECH AG (2,150,000 shares), WASATCH ADVISORS INC (1,659,513 shares), CITADEL ADVISORS LLC (1,398,793 shares), STATE STREET CORP (1,004,360 shares), Hillhouse Capital Management, Ltd. (1,000,000 shares), BANK OF AMERICA CORP /DE/ (931,485 shares), and RHENMAN & PARTNERS ASSET MANAGEMENT AB (833,154 shares).
This table shows the top 99 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.